[
  {
    "ts": null,
    "headline": "INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE",
    "summary": "PHILADELPHIA, June 3, 2025 /PRNewswire/ -- Berger Montague advises shareholders of Pfizer Inc. about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to...",
    "url": "https://finnhub.io/api/news?id=fc125b098433fb034db28b458ffe90df579b119901e625039b74164b7e037b96",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748973005,
      "headline": "INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE",
      "id": 134997799,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "PHILADELPHIA, June 3, 2025 /PRNewswire/ -- Berger Montague advises shareholders of Pfizer Inc. about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to...",
      "url": "https://finnhub.io/api/news?id=fc125b098433fb034db28b458ffe90df579b119901e625039b74164b7e037b96"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike",
    "summary": "MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.",
    "url": "https://finnhub.io/api/news?id=8949bed78e99f911790bf77ce843d3bb9b77af4575458f5413de3cf941d6d051",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748967360,
      "headline": "Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike",
      "id": 134985650,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.",
      "url": "https://finnhub.io/api/news?id=8949bed78e99f911790bf77ce843d3bb9b77af4575458f5413de3cf941d6d051"
    }
  },
  {
    "ts": null,
    "headline": "Top 4 Value Stocks to Buy as Trade Tensions Still Cloud H2 Outlook",
    "summary": "STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.",
    "url": "https://finnhub.io/api/news?id=f66d8347320cbdbd1c9288efa586480d676f8afd9a879fc15ae8dd6851937edc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748960640,
      "headline": "Top 4 Value Stocks to Buy as Trade Tensions Still Cloud H2 Outlook",
      "id": 134978527,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.",
      "url": "https://finnhub.io/api/news?id=f66d8347320cbdbd1c9288efa586480d676f8afd9a879fc15ae8dd6851937edc"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: I Should Have Sold Earlier (Downgrade)",
    "summary": "I downgrade Pfizer to 'Strong Sell' as its high dividend yield fails to offset persistent share price weakness and lack of upside. Click here to read more.",
    "url": "https://finnhub.io/api/news?id=16fd202a0a39c4be61edfd9cb4f781071ae681def43eaa506f1e8184593d45f6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748958732,
      "headline": "Pfizer: I Should Have Sold Earlier (Downgrade)",
      "id": 134982053,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1293330778/image_1293330778.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "I downgrade Pfizer to 'Strong Sell' as its high dividend yield fails to offset persistent share price weakness and lack of upside. Click here to read more.",
      "url": "https://finnhub.io/api/news?id=16fd202a0a39c4be61edfd9cb4f781071ae681def43eaa506f1e8184593d45f6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's R&D Optimization Delivers Great Results & Secure Dividends",
    "summary": "PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales erosion and patent challenges.",
    "url": "https://finnhub.io/api/news?id=ef6d0d2649b632795f3708aae2a40e65a16bef38bd74897b695c23ff630fa394",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748956938,
      "headline": "Pfizer's R&D Optimization Delivers Great Results & Secure Dividends",
      "id": 134981737,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159073119/image_2159073119.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales erosion and patent challenges.",
      "url": "https://finnhub.io/api/news?id=ef6d0d2649b632795f3708aae2a40e65a16bef38bd74897b695c23ff630fa394"
    }
  },
  {
    "ts": null,
    "headline": "How Moderna Went From Pandemic Hero to Vaccine Victim",
    "summary": "How Moderna Went From Pandemic Hero to Vaccine Victim",
    "url": "https://finnhub.io/api/news?id=db20f072e5d9c12a7824ec18b91569326b950f62fce56483a1b07c0f08b5a7b4",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748937540,
      "headline": "How Moderna Went From Pandemic Hero to Vaccine Victim",
      "id": 134985313,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "How Moderna Went From Pandemic Hero to Vaccine Victim",
      "url": "https://finnhub.io/api/news?id=db20f072e5d9c12a7824ec18b91569326b950f62fce56483a1b07c0f08b5a7b4"
    }
  },
  {
    "ts": null,
    "headline": "3 Safe Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 11.35% -- That Make for No-Brainer Buys in June",
    "summary": "Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.",
    "url": "https://finnhub.io/api/news?id=206684520b4134c483fd9d7c2601fdcd80090e603b495274da814b36e08bb6ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748934360,
      "headline": "3 Safe Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 11.35% -- That Make for No-Brainer Buys in June",
      "id": 134978528,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.",
      "url": "https://finnhub.io/api/news?id=206684520b4134c483fd9d7c2601fdcd80090e603b495274da814b36e08bb6ff"
    }
  },
  {
    "ts": null,
    "headline": "PFIZER INC : JP Morgan is Neutral",
    "summary": "In a research note published by Chris Schott, JP Morgan gives a Neutral rating to the stock. The target price remains unchanged at USD 30.",
    "url": "https://finnhub.io/api/news?id=f97ce1b3438b1c18530a726857cbe5e8e35e6c9bc6d4c6c2748431a610a479a5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748925381,
      "headline": "PFIZER INC : JP Morgan is Neutral",
      "id": 134974623,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "In a research note published by Chris Schott, JP Morgan gives a Neutral rating to the stock. The target price remains unchanged at USD 30.",
      "url": "https://finnhub.io/api/news?id=f97ce1b3438b1c18530a726857cbe5e8e35e6c9bc6d4c6c2748431a610a479a5"
    }
  }
]